4BIO portfolio company Orchard Therapeutics announces ADA-SCID follow-on results

Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID. 100% overall survival and 100% event free survival in patients treated with OTL-101 compared to 88% OS and 56% EvFS with historical HSCT overall at 24 months. Biologics License Application Submission Planned for the U.S. Read more at the company website.

ARCHIVE
SEARCH BY TAGS
FOLLOW US
4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2020 by 4BIO Ventures Management Ltd